W. Goldschmidts

Epstein-Barr virus genotypes in AIDS-associated lymphomas are similar to those in endemic Burkitt's lymphomas.

D. Shibata, K. Bhatia, I. Magrath, 1992, Leukemia.

Hemi‐ or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect

G. Gaidano, K. Bhatia, I. Magrath, 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.

I. Magrath, O. Alabaster, H. Sieverts, 1986, Cancer research.

Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide

B. Shiramizu, M. McManaway, R. Redner, 1990, The Lancet.

Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.

L. Schneider, R. Heaton, J. Rochon, 1998, Archives of neurology.

Characterization of Burkitt’s Lymphoma Cell Lines with Monoclonal Antibodies Using an ELISA Technique

G. Marti, I. Magrath, J. Sandlund, 1986 .

Neutralization of Epstein-Barr virus-induced ribonucleotide reductase with antibody to the major restricted early antigen polypeptide.

M. Ginsburg, G. Pearson, W. Goldschmidts, 1989, Virology.

A restricted component of the Epstein-Barr virus early antigen complex is structurally related to ribonucleotide reductase.

G. Pearson, W. Goldschmidts, J. Luka, 1987, Virology.

Inhibition of the EBV Lytic Cycle by Sequence Specific Antisense Oligonucleotides

I. Magrath, K. Bhatia, W. Goldschmidts, 1991 .

Perspectives from the National Institute of Mental Health: Preventing or living with aids

L. Mitnick, B. Vitiello, W. Pequegnat, 1996, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.